Explore: Biotech · Drug Discovery · Digital Health · Medtech · Seed · Series A
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim
The Boehringer Ingelheim Venture Fund (BIVF), established in 2010, is a €350M evergreen corporate venture fund that invests in first-in-class, disease-modifying therapeutics across various modalities, focusing on groundbreaking innovation in cancer (immuno-oncology & targeted therapy), regenerative medicine, auto-immunity, digital solutions, and infectious diseases (AMR). It primarily targets pre-clinical assets and platforms as a dedicated Seed/Series A investor, with global presence in the EU, US, and China, taking minority stakes and board seats to actively support portfolio companies aligned with Boehringer Ingelheim's strategic interests.
Boehringer Ingelheim Venture Fund (Boehringer Ingelheim) invests at seed and Series A, focuses on Biotech, Drug Discovery, Digital Health, Medtech and Diagnostics, backs founders in Global.
Stages
Sectors
Geographies
Headquarters
Germany
🔒 Team & partners
Sign in to view🔒 Live funding signals
Sign in to view🔒 Contacts
Sign in to viewSign in to see Boehringer Ingelheim Venture Fund's full profile
Team & partners, portfolio, live funding signals and contacts. Free account, Google sign-in.
Create free accountVerified 29 March 2026 · Sources: Fusion42 review
Frequently asked questions
- What does Boehringer Ingelheim Venture Fund invest in?
- Boehringer Ingelheim Venture Fund invests in Biotech, Drug Discovery, Digital Health, Medtech and Diagnostics at the seed and series-a stages.
- Which geographies does Boehringer Ingelheim Venture Fund focus on?
- Boehringer Ingelheim Venture Fund focuses on Global, and is headquartered in Germany.